• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix misses The Street on bottom-line leap

May 6, 2021 By Nancy Crotti

Ocular Therapeutix logoOcular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street.

The Bedford, Mass.–based eye disease therapeutic developer yesterday posted profits of $3.12 million, or $0.04 per share, on sales of $7.34 million for the three months ended March 31, 2021, for a bottom-line leap of 114% on sales growth of 181% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were –24¢, –4¢ behind Wall Street, while the company’s revenues missed the analysts’ projections by –6.5%.

“Our progress in the first quarter of 2021 was significant,” said company president & CEO Antony Mattessich in a news release.

“Revenue for Dextenza was up over 200% against the prior-year period and we achieved record quarterly, in-market sales in excess of 16,000 billable units, representing 15% sequential quarterly growth. Encouragingly, the momentum we saw in the first quarter has continued into the second quarter with estimated sales in excess of 8,000 billable units in April alone. Beyond Dextenza, we have made progress in advancing our pipeline of product candidates that continue to show potential to set the standard of care in their respective disease areas.”

Ocular Therapeutix did not offer financial guidance for the remainder of 2021.

OCUL shares were down –3.86% to $15.98 apiece this morning. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down slightly.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS